Navigation Links
Topaz Pharmaceuticals' Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
Date:7/11/2011

HORSHAM, Pa., July 11, 2011 /PRNewswire/ -- In a study sponsored by Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, scientists from the University of Massachusetts, Amherst presented data showing that a 0.5% ivermectin (IVM) cream formulation was active against lice eggs from permethrin resistant head lice.  The data were presented in a poster presentation on Saturday, July 9, 2011 at the 37th Annual Meeting of the Society for Pediatric Dermatology in Baltimore, Maryland.  

"These data build on our earlier work showing this ivermectin formulation is active against head lice," said John M. Clark, Ph.D., Professor of Veterinary and Animal Sciences, University of Massachusetts Amherst.  "The data suggest that a single treatment with 0.5% ivermectin cream has the potential to fully break the head louse life cycle.   If approved by the FDA, ivermectin cream has the potential to provide physicians with an attractive treatment option."  

In the study, permethrin resistant head lice were allowed to lay eggs in tufts of human hair.  Adult lice were removed and the tufts with eggs were exposed to 0.5% ivermectin cream, to vehicle only, or to unformulated, diluted ivermectin. After a 10-minute exposure, tufts were thoroughly rinsed and incubated.  Any hatched lice were placed onto new tufts and moved to a feeding cup.  The hatchability of treated eggs was not affected by ivermectin. No differences were detected between the mortality rate of eggs exposed to 0.5% ivermectin cream and those exposed to unformulated ivermectin.  The percent of hatched lice from eggs exposed to 0.5% ivermectin cream that took a blood meal, relative to eggs exposed to placebo, was significantly decreased (by 82-95%).  All hatched lice from eggs treated with 0.5% ivermectin cream died within 48 hours.  

About Ivermectin

Ivermectin is a broad-spectrum antiparasitic agent.  Its known mechanism of action is that it binds selectively to certain ion channels present in invertebrate nerve and muscle cells but not present in mammals. The resulting increase in permeability of the cell membrane causes the death of certain parasites.  First developed from a soil bacterium, widespread oral use of ivermectin, under the brand name Mectizan®, began in 1987 in sub-Saharan Africa to control river blindness (onchocerciasis) in humans.  More than one billion treatments of oral ivermectin have been administered to help alleviate the suffering caused by river blindness and lymphatic filariasis.  On June 7, 2011, FDA accepted the new drug application of Topaz Pharmaceuticals for the use of a novel topical form of ivermectin as a potential therapy to treat head lice.  This submission is presently under review by FDA.

About Topaz Pharmaceuticals

Topaz Pharmaceuticals Inc. is a privately held specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets. The company's lead investigational product is a topical cream formulation of ivermectin currently under development for the treatment of head lice infestations in children and adults which affect between six and 12 million people every year. Topaz has completed two phase 3 studies of ivermectin and has filed its new drug application for this potential indication. Topaz, headquartered in Horsham, PA, is backed by top-tier investors including Aisling Capital and Fidelity Biosciences.  For more information about Topaz Pharmaceuticals Inc., please visit www.topazpharma.com.

Contact Information
E. Blair Schoeb
Tel: 908-277-0386
blair@biotechcomm.com


'/>"/>
SOURCE Topaz Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA
2. Topaz Pharmaceuticals Names Dr. Mark Strobeck Chief Business Officer
3. Topaz Pharmaceuticals Announces Completion of Pivotal Phase 3 Trials of Ivermectin Topical Cream
4. Topaz Pharmaceuticals Names Bob Radie Chief Executive Officer
5. TOPAZ Technologies and ML Weekes & Company Announce Partnership
6. Shareholder Class Action Filed Against SciClone Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
8. TOPAZ Technologies and Tecniplast USA Launch RFID Mobile Census
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. Schiffrin Barroway Topaz & Kessler, LLP and Janet Jenner & Suggs, LLC Comment on Conagra Advisory Regarding Pot Pies Linked to Salmonella Outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Ethicon* today announced ... Inc., a privately held medical device company that ... for the surgical treatment of Gastroesophageal Reflux Disease ... of expanding its portfolio of minimally invasive options ... conditions. Financial terms of the transaction have not ...
(Date:3/23/2017)... , March 23, 2017  Additive Orthopaedics, ... announced that it has kicked off a multi-centered ... 3D printed bone segments. According to ... unique variable honeycomb lattice structures have already shown ... compared to current allograft wedges from which we ...
(Date:3/23/2017)... 23, 2017 Ascendis Pharma A/S (Nasdaq: ASND), ... to address significant unmet medical needs in rare diseases, ... call and webcast on Monday, April 3 during ENDO ... Orlando, Florida , to discuss new ... Growth Hormone, TransCon PTH and TransCon CNP). ...
Breaking Medicine Technology:
(Date:3/23/2017)... Austin, TX (PRWEB) , ... March 23, 2017 , ... ... fist-sized organs that pack a punch when it comes to maintaining good health. Every ... every 30 minutes, your kidneys filter every drop of your blood, eliminating waste, regulating ...
(Date:3/23/2017)... ... March 23, 2017 , ... The ... organized by HMP Communications Holdings, LLC, today announced that RestorixHealth® has ... network of wound centers interested in becoming Certified Wound Specialist Physicians (CWSP®). ...
(Date:3/23/2017)... ... March 23, 2017 , ... After raising more than $1.135 ... the most-funded travel pillow in crowdfunding history, has established a U.S. Headquarters ... popular travel innovation to Americans. , “We’re excited to be operating on U.S. shores, ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful ... foundation. As experts in dangerous situations the Inflow IQ team can help people. ... ripe, fresh, clean & refreshing knowledge systems that enhance life. , Authentically ...
Breaking Medicine News(10 mins):